Page last updated: 2024-10-28

ibuprofen and Gastric Ulcer

ibuprofen has been researched along with Gastric Ulcer in 91 studies

Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine

Research Excerpts

ExcerptRelevanceReference
"We performed two 24-week double-blind trials (REDUCE-1 and -2 (Registration Endoscopic Studies to Determine Ulcer Formation of HZT-501 Compared with Ibuprofen: Efficacy and Safety Studies)) to assess whether double-dose famotidine given in a single-tablet combination with ibuprofen (HZT-501) significantly reduces gastric and duodenal ulcers as compared with ibuprofen."9.16Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. ( Bello, AE; Grahn, AY; Kivitz, AJ; Laine, L; Schiff, MH; Taha, AS, 2012)
"This double-blind, multicentre, placebo-controlled, parallel-group study compared the incidence of gastroduodenal ulcers associated with valdecoxib 10 mg daily (q."9.10Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. ( Agrawal, NM; Kent, JD; Recker, DP; Sikes, DH; Verburg, KM; Zhao, WW, 2002)
"The cumulative incidence of gastroduodenal ulcers >/=3 mm with rofecoxib (25 or 50 mg once daily) was significantly (P < 0."9.09A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. ( Bath, R; Bolognese, J; Harper, S; Johanson, J; Laine, L; Quan, H; Schwartz, H; Simon, T; Stern, S, 1999)
"Although anti-inflammatory doses of ibuprofen are very effective in treating the signs and symptoms of osteoarthritis (OA), they come with an increased risk for gastrointestinal damage which can limit their use and decrease patient adherence to therapy."8.90Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. ( Bello, AE; Grahn, AY; Holt, RJ; Kent, JD; Rice, P, 2014)
"Single-tablet ibuprofen/famotidine is approved by the US Food and Drug Administration for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal (GI) ulcers in patients taking ibuprofen for those indications."7.79Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis. ( Holt, RJ; Johnson, KE; Kent, JD; Kuan, R; Malone, D; Peura, DA, 2013)
"Limited data to date indicate that ibuprofen, when used in large doses to treat the pulmonary manifestations of cystic fibrosis, is relatively safe."7.70Pyloric channel stricture secondary to high-dose ibuprofen therapy in a patient with cystic fibrosis. ( Bell, EA; Foote, JM; Grothe, R; Wellendorf, J; Zivkovich, V, 1999)
"Most patients (65%) finished the trial, with 76% contributing data at 6 months, and 21% withdrew due to adverse effects."6.80One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia. ( Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015)
"Ibuprofen/famotidine was generally well tolerated, with a tolerability profile consistent with those established for the individual agents."6.49Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. ( Deeks, ED, 2013)
"Dimethylglycine did not produce any significant change in acid secretion, unlike famotidine."5.31Effect of dimethylglycine on gastric ulcers in rats. ( Hariganesh, K; Prathiba, J, 2000)
"In the pivotal efficacy and safety trials, discontinuation rates due to any cause and dyspepsia were significantly lower for the ibuprofen/famotidine combination versus ibuprofen alone."5.20One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension. ( Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015)
"We performed two 24-week double-blind trials (REDUCE-1 and -2 (Registration Endoscopic Studies to Determine Ulcer Formation of HZT-501 Compared with Ibuprofen: Efficacy and Safety Studies)) to assess whether double-dose famotidine given in a single-tablet combination with ibuprofen (HZT-501) significantly reduces gastric and duodenal ulcers as compared with ibuprofen."5.16Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. ( Bello, AE; Grahn, AY; Kivitz, AJ; Laine, L; Schiff, MH; Taha, AS, 2012)
"Patients with osteoarthritis (age, >or=50 y) were randomized to receive lumiracoxib 400 mg once daily, naproxen 500 mg twice daily, or ibuprofen 800 mg 3 times daily for 12 months."5.12Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. ( Gitton, X; Hawkey, CJ; Krammer, G; Matchaba, P; Mellein, B; Richard, D; Sallstig, P; Smalley, W; Stricker, K; Weinstein, WM, 2007)
"Osteoarthritis patients > or =50 years of age without ulcers or erosive esophagitis at baseline endoscopy were assigned randomly to placebo, enteric-coated aspirin 81 mg/day, rofecoxib 25 mg combined with aspirin 81 mg/day, or ibuprofen 800 mg 3 times a day."5.11Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. ( Laine, L; Maller, ES; Quan, H; Simon, T; Yu, C, 2004)
"This double-blind, multicentre, placebo-controlled, parallel-group study compared the incidence of gastroduodenal ulcers associated with valdecoxib 10 mg daily (q."5.10Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. ( Agrawal, NM; Kent, JD; Recker, DP; Sikes, DH; Verburg, KM; Zhao, WW, 2002)
"We analysed pooled data from two identical double-blind, randomized, 12-week endoscopy studies which compared the gastroduodenal toxicity of placebo (n=371), rofecoxib 25 mg (n=390), rofecoxib 50 mg (n=379), and ibuprofen 2400 mg daily (n=376) in patients with osteoarthritis."5.09Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. ( Bolognese, JA; Harper, SE; Hawkey, CJ; Laine, L; Mortensen, E; Quan, HU, 2001)
"The cumulative incidence of gastroduodenal ulcers >/=3 mm with rofecoxib (25 or 50 mg once daily) was significantly (P < 0."5.09A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. ( Bath, R; Bolognese, J; Harper, S; Johanson, J; Laine, L; Quan, H; Schwartz, H; Simon, T; Stern, S, 1999)
"Although anti-inflammatory doses of ibuprofen are very effective in treating the signs and symptoms of osteoarthritis (OA), they come with an increased risk for gastrointestinal damage which can limit their use and decrease patient adherence to therapy."4.90Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. ( Bello, AE; Grahn, AY; Holt, RJ; Kent, JD; Rice, P, 2014)
" The diagnoses made by the community pharmacists from the pseudo-patients complaints were compared with the expected diagnosis of uncomplicated gastric ulcer caused by the use of ibuprofen."3.91Management of uncomplicated gastric ulcer in community pharmacy: a pseudo-patient study. ( Adelakun, AR; Showande, SJ, 2019)
"Single-tablet ibuprofen/famotidine is approved by the US Food and Drug Administration for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal (GI) ulcers in patients taking ibuprofen for those indications."3.79Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis. ( Holt, RJ; Johnson, KE; Kent, JD; Kuan, R; Malone, D; Peura, DA, 2013)
"The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers."3.77A fixed-dose combination ibuprofen and famotidine (Duexis). ( , 2011)
" Acute gastric ulceration in rats was produced by oral administration of ethanol and ibuprofen."3.74Antiulcerogenic activity of bark extract of Tabebuia avellanedae, Lorentz ex Griseb. ( Baggio, CH; dos Santos, AC; dos Santos, EP; Freitas, CS; Marques, MC; Mayer, B; Otuki, MF; Pizzolatti, MG; Twardowschy, A; Zacarias, AA, 2008)
"Over a 6-month period, two patients presented to a community hospital emergency department with perforated gastric ulcers as the result of recreational misuse of over-the-counter ibuprofen-codeine preparations."3.74Nurofen Plus misuse: an emerging cause of perforated gastric ulcer. ( Dutch, MJ, 2008)
" In a chronic model, by acetic acid-induced gastric ulcers, COX-2 was expressed at 7 days and was also associated with PGE(2) increase."3.73COX expression and PGE(2) and PGD(2) production in experimental acute and chronic gastric lesions. ( Alarcón de la Lastra, C; Bruseghini, L; Manuel Herrerias, J; Motilva, V; Sánchez-Fidalgo, S, 2005)
"The objective of the present study has been to advance knowledge of the gastric role played by the amino acid L-Arginine (L-Arg) in the evolution of a chronic gastric ulcer."3.73Administration of L-arginine reduces the delay of the healing process caused by ibuprofen. Implication of COX and growth factors expression. ( Bruseghini, L; Esteras, A; Illanes, M; Martín-Lacave, I; Motilva, V; Sánchez-Fidalgo, S, 2005)
"To elucidate the role of cyclooxygenase-2, we compared the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, and ibuprofen, a nonselective cyclooxygenase inhibitor, on the evolution of acetic-acid-induced gastric ulcers in rats, evaluating growth factor expression, the angiogenic process, cell proliferation and cell apoptosis."3.72Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor. ( Illanes, M; Martín-Lacave, I; Motilva, V; Sánchez-Fidalgo, S, 2004)
"Limited data to date indicate that ibuprofen, when used in large doses to treat the pulmonary manifestations of cystic fibrosis, is relatively safe."3.70Pyloric channel stricture secondary to high-dose ibuprofen therapy in a patient with cystic fibrosis. ( Bell, EA; Foote, JM; Grothe, R; Wellendorf, J; Zivkovich, V, 1999)
" In rat adjuvant arthritis, NS-398 showed a therapeutic effect comparable to that seen with loxoprofen but less than that seen with indomethacin and diclofenac."3.68NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. ( Arai, I; Futaki, N; Hamasaka, Y; Higuchi, S; Iizuka, H; Otomo, S; Yoshikawa, K, 1993)
"A 3-year-old Chow Chow was examined because of a 2-week history of vomiting and anorexia after administration of 200 mg of ibuprofen."3.68Gastric perforation associated with administration of ibuprofen in a dog. ( Fingland, RB; Godshalk, CP; Roush, JK; Sikkema, D; Vorhies, MW, 1992)
"Most patients (65%) finished the trial, with 76% contributing data at 6 months, and 21% withdrew due to adverse effects."2.80One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia. ( Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015)
" Each subject took, over four separate 10-day dosing periods, ibuprofen 400 mg t."2.69Dose-dependent effects of ketoprofen on the human gastric mucosa in comparison with ibuprofen. ( Courtauld, E; Donnelly, MT; Hawkey, CJ; Richardson, P; Stack, WA, 2000)
"Ibuprofen/famotidine was generally well tolerated, with a tolerability profile consistent with those established for the individual agents."2.49Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. ( Deeks, ED, 2013)
"Ibuprofen is an inexpensive short-acting NSAID and is readily available in liquid formulation for administration to bottle-fed calves."1.43Adverse effects of a 10-day course of ibuprofen in Holstein calves. ( Anderson, M; Behrens, N; Carvallo Chaigneau, FR; Gershwin, LJ; Gunnarson, B; McEligot, H; Walsh, P, 2016)
" We present the case of a previously healthy 3-year-old boy who developed severe chronic gastric outlet obstruction and antral stenosis after a short-term ingestion of liquid ibuprofen at a dosage not thought to be associated with unfavorable effects."1.39Pneumatic pyloric dilatation for the treatment of gastric outlet obstruction in a child. ( Alvisi, P; Billi, P; Fascetti Leon, F; Gobbi, D; Lambertini, A; Lima, M, 2013)
" A small amount of carrier phospholipid significantly increases the rate and the extent of dissolution, which may increase the bioavailability of ibuprofen."1.38Ibuprofen-phospholipid solid dispersions: improved dissolution and gastric tolerance. ( Brausch, JF; Hussain, MD; Saxena, V; Talukder, RM, 2012)
"In ibuprofen-treated rats, the lipid peroxidation measured as thiobarbituric acid reactive substances (TBARS), a marker for free radical-induced tissue damage, is also significantly decreased by taurine."1.32Taurine prevents Ibuprofen-induced gastric mucosal lesions and influences endogenous antioxidant status of stomach in rats. ( Balasubramanian, T; Felix, AJ; Somasundaram, M, 2004)
"Dimethylglycine did not produce any significant change in acid secretion, unlike famotidine."1.31Effect of dimethylglycine on gastric ulcers in rats. ( Hariganesh, K; Prathiba, J, 2000)
" Although this study failed to describe a dose-response relationship, it appears that there are significant breed differences in susceptibility to GIU subsequent to ibuprofen exposure."1.30A case-control study of acute ibuprofen toxicity in dogs. ( Hungerford, LL; Poortinga, EW, 1998)
" Following clinical observations that this drug combination induces significant adverse effects, its gastric toxicity was investigated in rats."1.28Potentiation of gastric toxicity of ibuprofen by paracetamol in the rat. ( Bhattacharya, SK; Goel, RK; Tandon, R, 1991)
"Acetaminophen has been proposed as an agent which protects the gastric mucosa against damage induced by aspirin and other non-steroidal anti-inflammatory agents."1.27Effect of acetaminophen on human gastric mucosal injury caused by ibuprofen. ( Lanza, FL; Nelson, RS; Rack, MF; Royer, GL; Schwartz, JH; Seckman, CE, 1986)
"Ibuprofen was observed to modulate some immunological phenomena with marked predominance of immunosuppressive component."1.27Selected pharmacological and immunopharmacological indices of ibuprofen. ( Giełdanowski, J, 1987)
"Butibufen was within the potency range of ibuprofen as an antipyretic and analgesic agent and greater than that of acetylsalicylic acid."1.26Some aspects of the pharmacology of butibufen, a non-steroidal anti-inflammatory agent. ( Aparicio, L, 1977)
" The degree of gastric or intestinal irritation seen with dosing of other drugs was as follows; indomethacin greater than diclofenac Na greater than ibuprofen greater than aspirin greater than phenylbutazone or indomethacin greater than CH-800 = diclofenac Na greater than ibuprofen greater than phenylbutazone, respectively."1.26[Irritative activity of a new anti-inflammatory agent 4-(p-chorophenyl)-2-phenyl-5-thiazoleacetic acid (CH-800) on the gastrointestinal tract in rats (author's transl)]. ( Ohtsuki, H; Okabe, S; Tabata, K, 1979)

Research

Studies (91)

TimeframeStudies, this research(%)All Research%
pre-199010 (10.99)18.7374
1990's14 (15.38)18.2507
2000's33 (36.26)29.6817
2010's32 (35.16)24.3611
2020's2 (2.20)2.80

Authors

AuthorsStudies
Hino, K1
Nakamura, H1
Nagai, Y1
Uno, H1
Nishimura, H1
Velázquez, C1
Praveen Rao, PN2
Knaus, EE3
Metwally, KA1
Yaseen, SH1
Lashine, el-SM1
El-Fayomi, HM1
El-Sadek, ME1
Velázquez, CA2
Citro, ML1
Keefer, LK1
Chatterjee, NR1
Kulkarni, AA1
Ghulekar, SP1
Akhter, M1
Husain, A1
Azad, B1
Ajmal, M1
Huang, Z1
Abdellatif, KR2
Chowdhury, MA1
Reisz, JA1
DuMond, JF1
King, SB1
Hegazy, GH1
Ali, HI1
Redasani, VK1
Bari, SB1
Navarro, L1
Rosell, G1
Sánchez, S1
Boixareu, N1
Pors, K1
Pouplana, R1
Campanera, JM1
Pujol, MD1
Meijuan, Z1
Yu, P1
Yuan, J1
Yu, T1
Sun, D2
Showande, SJ1
Adelakun, AR1
Panda, SS1
Girgis, AS1
Honkanadavar, HH1
George, RF1
Srour, AM1
Yehiyan, A1
Barman, S1
Varia, H1
Pettit, S1
Kaur, A1
Pathak, DP1
Sharma, V1
Narasimhan, B1
Sharma, P1
Mathur, R1
Wakode, S1
Kuan, R1
Holt, RJ5
Johnson, KE1
Kent, JD6
Peura, DA1
Malone, D1
Gobbi, D1
Billi, P1
Fascetti Leon, F1
Alvisi, P1
Lambertini, A1
Lima, M1
Deeks, ED1
Tuskey, A1
Peura, D1
Fukushima, E1
Monoi, N1
Mikoshiba, S1
Hirayama, Y1
Serizawa, T1
Adachi, K1
Koide, M1
Ohdera, M1
Murakoshi, M1
Kato, H1
Bello, AE5
Grahn, AY4
Rice, P1
Ball, J2
Taha, AS2
Shkair, AM1
Shakya, AK1
Raghavendra, NM1
Naik, RR1
Abdelgawad, MA1
Elshemy, HA1
Alsayed, SS1
Walsh, P1
Carvallo Chaigneau, FR1
Anderson, M1
Behrens, N1
McEligot, H1
Gunnarson, B1
Gershwin, LJ1
Liu, J1
He, J1
Yang, C1
Hu, T1
Zhang, L1
Cao, H1
Tong, AP1
Song, X1
Xie, Y1
He, G1
Guo, G1
Luo, Y1
Cheng, P1
Zheng, Y1
Lanza, FL3
Marathi, UK1
Anand, BS1
Lichtenberger, LM1
Twardowschy, A1
Freitas, CS1
Baggio, CH1
Mayer, B1
dos Santos, AC1
Pizzolatti, MG1
Zacarias, AA1
dos Santos, EP1
Otuki, MF1
Marques, MC1
Amir, M2
Kumar, S1
Girard, P1
Coppé, MC1
Pansart, Y1
Gillardin, JM1
Caunedo-Alvarez, A1
Gómez-Rodríguez, BJ1
Romero-Vázquez, J1
Argüelles-Arias, F1
Romero-Castro, R1
García-Montes, JM1
Pellicer-Bautista, FJ1
Herrerías-Gutiérrez, JM1
Saifullah, K1
Akhter, W1
Rasheed, A1
Kumar, CK1
Mishra, A1
Raval, JP1
Gandhi, AN1
Akhaja, TN1
Myangar, KN1
Patel, NH1
Hussain, MD1
Saxena, V1
Brausch, JF1
Talukder, RM1
Laine, L4
Kivitz, AJ1
Schiff, MH1
Chan, FK1
Uzgören-Baran, A1
Tel, BC1
Sarıgöl, D1
Oztürk, Eİ1
Kazkayası, I1
Okay, G1
Ertan, M1
Tozkoparan, B1
Chandiran, S1
Vyas, S1
Sharma, N1
Sharma, M1
Sikes, DH1
Agrawal, NM1
Zhao, WW1
Recker, DP1
Verburg, KM1
Hunt, RH1
Harper, S2
Callegari, P1
Yu, C2
Quan, H4
Evans, J1
James, C1
Bowen, B1
Rashid, F1
Cocco, MT1
Congiu, C1
Onnis, V1
Morelli, M1
Cauli, O1
Shostak, NA1
Riabkova, AA1
Savel'ev, VS1
Maliarova, LP1
Makhlouf, AA1
Maklad, YA1
Sudheer Kumar, M1
Sridhar Reddy, B1
Kiran Babu, S1
Bhilegaonkar, PM1
Shirwaikar, A1
Unnikrishnan, MK1
Maller, ES1
Simon, T2
Summerton, N1
Sánchez-Fidalgo, S3
Martín-Lacave, I2
Illanes, M2
Motilva, V3
Balasubramanian, T1
Somasundaram, M1
Felix, AJ1
Alarcón de la Lastra, C1
Bruseghini, L2
Manuel Herrerias, J1
Esteras, A1
Narayan, S1
Devi, RS1
Srinivasan, P1
Shyamala Devi, CS1
Zhao, X1
Tao, X1
Wei, D1
Song, Q1
Gambero, A1
Maróstica, M1
Becker, TL1
Pedrazzoli, J1
Berezin, SH1
Bostwick, HE1
Halata, MS1
Feerick, J1
Newman, LJ1
Medow, MS1
Hawkey, CJ3
Weinstein, WM1
Smalley, W1
Gitton, X1
Sallstig, P1
Stricker, K1
Krammer, G1
Mellein, B1
Richard, D1
Matchaba, P1
Dutch, MJ1
Diamantis, W1
Melton, J1
Sofia, RD1
Ciofalo, VB1
Parmar, NS1
Ghosh, MN1
Lems, WF1
van Berge Henegouwen, GP1
Bijlsma, JW1
Wagner, KA1
Nandi, J1
King, RL1
Levine, RA1
Smith, KJ1
Taylor, DH1
Futaki, N1
Yoshikawa, K1
Hamasaka, Y1
Arai, I1
Higuchi, S1
Iizuka, H1
Otomo, S1
Villar, D1
Buck, WB1
Gonzalez, JM1
Poortinga, EW1
Hungerford, LL1
Rack, MF2
Simon, TJ1
Bolognese, JA2
Hoover, ME1
Wilson, FR1
Harper, SE2
Bell, EA1
Grothe, R1
Zivkovich, V1
Foote, JM1
Wellendorf, J1
Bath, R1
Johanson, J1
Schwartz, H1
Stern, S1
Bolognese, J1
Pfau, PR1
Lichenstein, GR1
Kaufman, DW1
Kelly, JP1
Wiholm, BE1
Laszlo, A1
Sheehan, JE1
Koff, RS1
Shapiro, S1
Donnelly, MT1
Richardson, P1
Courtauld, E1
Stack, WA1
Andrade, A1
Namora, SF1
Woisky, RG1
Wiezel, G1
Najjar, R1
Sertié, JA1
de Oliveira Silva, D1
Hariganesh, K1
Prathiba, J1
Bansal, AK2
Khar, RK2
Dubey, R2
Sharma, AK2
Quan, HU1
Mortensen, E1
Jüni, P1
Rutjes, AW1
Dieppe, PA1
Tabata, K1
Ohtsuki, H1
Okabe, S1
Aparicio, L1
Godshalk, CP1
Roush, JK1
Fingland, RB1
Sikkema, D1
Vorhies, MW1
Skriabin, ON1
Baranchuk, VN1
Manyshev, VG1
Kurygin, AA1
Bhattacharya, SK2
Goel, RK1
Tandon, R1
Puscas, I1
Hajdu, A1
Buzás, G1
Bernáth, Z1
Somerville, K1
Faulkner, G1
Langman, M1
Giełdanowski, J1
Porkodi, R1
Raghuram, K1
Parthiban, M1
Chandrasekaran, AN1
Royer, GL1
Nelson, RS1
Seckman, CE1
Schwartz, JH1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Open-Label Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-Steroidal Anti-Inflammatory Drug Treatment[NCT00984815]Phase 386 participants (Actual)Interventional2009-09-30Completed
A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment[NCT00450658]Phase 3627 participants (Actual)Interventional2007-03-31Completed
A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment[NCT00450216]Phase 3906 participants (Actual)Interventional2007-03-31Completed
A Single Arm, Open-label Pilot Trial Examining the Effects of Pau d' Arco on Primary Dysmenorrhea in Reproductive Age Women[NCT04245540]Early Phase 112 participants (Actual)Interventional2019-07-30Completed
Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744]101 participants (Actual)Interventional2012-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in the Non-pain Symptoms Scale of the Severity of Dyspepsia Assessment (SODA) Questionnaire at 54 Weeks

The non-pain symptom scale of the SODA questionnaire ranges from 7 - 35. Change from baseline compares the score at Week 54 to the baseline score for each participant that completed the non-pain symptom questions of the SODA questionnaire at baseline and Week 54. Higher scores indicate greater symptom severity and therefore a negative mean change from baseline is indicative of an improvement in symptoms. (NCT00984815)
Timeframe: Baseline and 54 Weeks

InterventionScores on a scale (Mean)
HZT-501-1.44

Change From Baseline in the Pain Intensity Scale of the Severity of Dyspepsia Assessment (SODA) Questionnaire at 54 Weeks

The pain intensity scale of the SODA questionnaire ranges from 2 - 47. Change from baseline compares the score at Week 54 to the baseline score for each participant who completed the pain intensity questions of the SODA questionnaire at baseline and Week 54. Higher scores indicate greater symptom severity and therefore a negative mean change from baseline is indicative of an improvement in symptoms. (NCT00984815)
Timeframe: Baseline and 54 Weeks

InterventionScores on a scale (Mean)
HZT-501-3.22

Change From Baseline in the Satisfaction With Dyspepsia-Related Health Scale of the Severity of Dyspepsia Assessment (SODA) Questionnaire at 54 Weeks

The satisfaction with dyspepsia-related health scale of the SODA questionnaire ranges from 2 - 23. Change from baseline compares the score at Week 54 to the baseline score for each participant who completed the Satisfaction questions of the SODA questionnaire at baseline and Week 54. A positive change from baseline in the SODA satisfaction scale represents a participant's overall improved satisfaction with their dyspepsia-related health. (NCT00984815)
Timeframe: Baseline and 54 Weeks

InterventionScores on a scale (Mean)
HZT-5012.69

Number of Participants With Treatment Emergent Adverse Events

(NCT00984815)
Timeframe: 54 weeks

Interventionparticipants (Number)
HZT-50176

Number of Subjects Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period.

The secondary efficacy endpoint was the number of subjects with duodenal ulcer at any time throughout the 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks

Interventionparticipants (Number)
HZT-5013
Ibuprofen9

Number of Subjects Who Develop Endoscopically-diagnosed Gastric Ulcers During the 24-week Treatment Period.

The secondary efficacy endpoint was the number of subjects with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks

Interventionparticipants (Number)
HZT-50137
Ibuprofen34

Number of Subjects Who Develop Endoscopically-diagnosed Upper Gastrointestinal Ulcers Confirmed by Endoscopy.

The primary efficacy endpoint was the number of subjects with upper gastrointestinal (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks

Interventionparticipants (Number)
HZT-50140
Ibuprofen38

The Incidence Rate of NSAID-associated Serious Gastrointestinal Complications.

The secondary efficacy endpoint was the number of subjects developing a NSAID-associated serious GI complication at any time throughout 6 months of treatment. A NSAID-associated serious GI complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or GI bleeding. (NCT00450658)
Timeframe: 24 weeks

Interventionparticipants (Number)
HZT-5010
Ibuprofen0

Number of Participants Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period.

The secondary efficacy endpoint was the number of participants with duodenal ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks

Interventionparticipants (Number)
HZT-5018
Ibuprofen14

Number of Participants Who Develop Endoscopically-diagnosed Gastric Ulcers

The primary efficacy endpoint was the number of participants with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks

Interventionparticipants (Number)
HZT-50155
Ibuprofen52

Number of Participants Who Develop Endoscopically-diagnosed Upper Gastrointestinal (UGI) Ulcers During the 24-week Treatment Period.

The secondary efficacy endpoint was the number of participants with UGI (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks

Interventionparticipants (Number)
HZT-50163
Ibuprofen61

The Number of Participants Developing Non-steroidal Anti-inflammatory (NSAID)Associated Serious Gastrointestinal Complications (Perforation of Ulcers, Gastric Outlet Obstruction Due to Ulcers, Gastrointestinal Bleeding)

The secondary efficacy endpoint was the number of participants developing a NSAID-associated serious gastrointestinal complication at any time throughout 24 weeks of treatment. A NSAID-associated serious gastrointestinal complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or gastrointestinal bleeding. (NCT00450216)
Timeframe: 24 weeks

Interventionparticpants (Number)
HZT-5013
Ibuprofen0

Number of Participants With Ulcer Recurrence

Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month

Interventionparticipants (Number)
Proton Pump Inhibitor Group1
Histamine-2 Receptor Antagonist Group7

Reviews

5 reviews available for ibuprofen and Gastric Ulcer

ArticleYear
Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy.
    Clinical drug investigation, 2013, Volume: 33, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Drug Interactions; Duodenal Ulcer; Famot

2013
The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.
    Arthritis research & therapy, 2013, Volume: 15 Suppl 3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Therapy, Combination; Famotidine; G

2013
Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials.
    Postgraduate medicine, 2014, Volume: 126, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Combinations; Duodenal Ulcer; Famot

2014
['Stomach-friendly' NSAIDs: careful optimism?].
    Nederlands tijdschrift voor geneeskunde, 1995, Nov-04, Volume: 139, Issue:44

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Gastritis; Humans; Ibuprofen; Misopro

1995
Ibuprofen, aspirin and acetaminophen toxicosis and treatment in dogs and cats.
    Veterinary and human toxicology, 1998, Volume: 40, Issue:3

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin;

1998

Trials

14 trials available for ibuprofen and Gastric Ulcer

ArticleYear
One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia.
    Current medical research and opinion, 2015, Volume: 31, Issue:3

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Combinations; Drug

2015
One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension.
    Current medical research and opinion, 2015, Volume: 31, Issue:3

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Combinations; Drug

2015
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
    The Physician and sportsmedicine, 2015, Volume: 43, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age

2015
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
    The Physician and sportsmedicine, 2015, Volume: 43, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age

2015
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
    The Physician and sportsmedicine, 2015, Volume: 43, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age

2015
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
    The Physician and sportsmedicine, 2015, Volume: 43, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age

2015
Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients.
    Alimentary pharmacology & therapeutics, 2008, Aug-15, Volume: 28, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-

2008
Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers.
    The American journal of gastroenterology, 2012, Volume: 107, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-

2012
Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.
    European journal of gastroenterology & hepatology, 2002, Volume: 14, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cyclo

2002
Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib.
    Alimentary pharmacology & therapeutics, 2003, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase

2003
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.
    Gastroenterology, 2004, Volume: 127, Issue:2

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitor

2004
Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
    Gastroenterology, 2007, Volume: 133, Issue:1

    Topics: Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclof

2007
Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen.
    Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:6

    Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenas

1999
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.
    Gastroenterology, 1999, Volume: 117, Issue:4

    Topics: Aged; Aged, 80 and over; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; D

1999
Dose-dependent effects of ketoprofen on the human gastric mucosa in comparison with ibuprofen.
    Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:5

    Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Dose-Respo

2000
Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.
    Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:10

    Topics: Aged; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method;

2001
Prevention of non-steroidal anti-inflammatory agents induced acute gastric mucosal lesions by carbonic anhydrase inhibitors. An endoscopic study.
    Acta physiologica Hungarica, 1989, Volume: 73, Issue:2-3

    Topics: Acetazolamide; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastric Mucosa; Gastroscopy;

1989

Other Studies

72 other studies available for ibuprofen and Gastric Ulcer

ArticleYear
Nonsteroidal antiinflammatory agents. 2. [(Heteroarylamino)phenyl]alkanoic acids.
    Journal of medicinal chemistry, 1983, Volume: 26, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Carboxylic Acids; Carrageenan; Edema; Fe

1983
Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies.
    Journal of medicinal chemistry, 2005, Jun-16, Volume: 48, Issue:12

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azo Compounds; Cyclooxygenase 1; Cyclooxy

2005
Non-carboxylic analogues of arylpropionic acids: synthesis, anti-inflammatory activity and ulcerogenic potential.
    European journal of medicinal chemistry, 2007, Volume: 42, Issue:2

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Flurbiprofen; Ibuprofen; Male; Naproxen; Propionat

2007
O2-acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): synthesis, nitric oxide release, and biological evaluation studies.
    Bioorganic & medicinal chemistry, 2007, Jul-15, Volume: 15, Issue:14

    Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cycloo

2007
Synthesis, pharmacological activity and hydrolytic behavior of ethylenediamine and benzathine conjugates of ibuprofen.
    European journal of medicinal chemistry, 2008, Volume: 43, Issue:12

    Topics: Administration, Oral; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Dis

2008
Aroylpropionic acid based 2,5-disubstituted-1,3,4-oxadiazoles: synthesis and their anti-inflammatory and analgesic activities.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:6

    Topics: Acute Disease; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclizatio

2009
Ethanesulfohydroxamic acid ester prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs): synthesis, nitric oxide and nitroxyl release, cyclooxygenase inhibition, anti-inflammatory, and ulcerogenicity index studies.
    Journal of medicinal chemistry, 2011, Mar-10, Volume: 54, Issue:5

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase Inhibitors; Edema; Est

2011
Design, synthesis, biological evaluation, and comparative Cox1 and Cox2 docking of p-substituted benzylidenamino phenyl esters of ibuprofenic and mefenamic acids.
    Bioorganic & medicinal chemistry, 2012, Feb-01, Volume: 20, Issue:3

    Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Drug Design; Edema; Ibupr

2012
Synthesis and evaluation of mutual prodrugs of ibuprofen with menthol, thymol and eugenol.
    European journal of medicinal chemistry, 2012, Volume: 56

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Edema; Eugenol; Female; Hydrogen-Ion

2012
Synthesis and biological properties of aryl methyl sulfones.
    Bioorganic & medicinal chemistry, 2018, 08-07, Volume: 26, Issue:14

    Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Carrageenan; Dimet

2018
Stomach ulcer caused by mistakenly oral medication of 14,400 mg ibuprofen: A case report.
    Medicine, 2023, May-19, Volume: 102, Issue:20

    Topics: Adult; Duodenal Ulcer; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylo

2023
Management of uncomplicated gastric ulcer in community pharmacy: a pseudo-patient study.
    International journal of clinical pharmacy, 2019, Volume: 41, Issue:6

    Topics: Clinical Competence; Community Pharmacy Services; Cross-Sectional Studies; Diagnosis, Differential;

2019
Synthesis of new ibuprofen hybrid conjugates as potential anti-inflammatory and analgesic agents.
    Future medicinal chemistry, 2020, Volume: 12, Issue:15

    Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygena

2020
Short-course high-dose ibuprofen causing both early and delayed jejunal perforations in a non-smoking man.
    BMJ case reports, 2017, Dec-22, Volume: 2017

    Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Back Pain; Humans; Ibuprofen; Intestinal Pe

2017
Synthesis, biological evaluation and docking study of N-(2-(3,4,5-trimethoxybenzyl)benzoxazole-5-yl) benzamide derivatives as selective COX-2 inhibitor and anti-inflammatory agents.
    Bioorganic chemistry, 2018, Volume: 81

    Topics: Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Benzamides; Benzoxazoles; Carrageenan; Cycloox

2018
Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis.
    Clinical therapeutics, 2013, Volume: 35, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Drug Combinations

2013
Pneumatic pyloric dilatation for the treatment of gastric outlet obstruction in a child.
    Pediatrics international : official journal of the Japan Pediatric Society, 2013, Volume: 55, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Combined Modality Therapy; Dilatation; Ga

2013
Protective effects of acetaminophen on ibuprofen-induced gastric mucosal damage in rats with associated suppression of matrix metalloproteinase.
    The Journal of pharmacology and experimental therapeutics, 2014, Volume: 349, Issue:1

    Topics: Acetaminophen; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cytokines; Do

2014
The ibuprofen-famotidine combined pill - a promise fulfilled.
    Current medical research and opinion, 2015, Volume: 31, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Dyspepsia; Famotidine; Female; Histamine H2 Antagonists; Hu

2015
Molecular Modeling, Synthesis and Pharmacological Evaluation of 1,3,4- Thiadiazoles as Anti-inflammatory and Analgesic Agents.
    Medicinal chemistry (Shariqah (United Arab Emirates)), 2016, Volume: 12, Issue:1

    Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Cy

2016
Design, synthesis and biological screening of new 4-thiazolidinone derivatives with promising COX-2 selectivity, anti-inflammatory activity and gastric safety profile.
    Bioorganic chemistry, 2016, Volume: 64

    Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 I

2016
Adverse effects of a 10-day course of ibuprofen in Holstein calves.
    Journal of veterinary pharmacology and therapeutics, 2016, Volume: 39, Issue:5

    Topics: Abomasum; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Blood Urea Nitrogen; C

2016
Gastroprotective effects of several H2RAs on ibuprofen-induced gastric ulcer in rats.
    Life sciences, 2016, Mar-15, Volume: 149

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Gastric Mucosa; Histamine H2 Antagonists; Ibuprofe

2016
Antiulcerogenic activity of bark extract of Tabebuia avellanedae, Lorentz ex Griseb.
    Journal of ethnopharmacology, 2008, Aug-13, Volume: 118, Issue:3

    Topics: Animals; Anti-Ulcer Agents; Female; Gastric Acid; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Ibupr

2008
Synthesis and evaluation of anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation properties of ibuprofen derivatives.
    Acta pharmaceutica (Zagreb, Croatia), 2007, Volume: 57, Issue:1

    Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Edema; Female; Gastric Mu

2007
Gastroprotective effect of Saccharomyces boulardii in a rat model of ibuprofen-induced gastric ulcer.
    Pharmacology, 2010, Volume: 85, Issue:3

    Topics: Animals; Body Weight; Cytoprotection; Disease Models, Animal; Gastric Mucosa; Ibuprofen; Male; Nitra

2010
Macroscopic small bowel mucosal injury caused by chronic nonsteroidal anti-inflammatory drugs (NSAID) use as assessed by capsule endoscopy.
    Revista espanola de enfermedades digestivas, 2010, Volume: 102, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Capsule Endoscopy; Cyclooxygenase 2 Inhibitors

2010
Design, synthesis and pharmacological evaluation of novel azole derivatives of aryl acetic acid as anti-inflammatory and analgesic agents.
    Journal of enzyme inhibition and medicinal chemistry, 2011, Volume: 26, Issue:1

    Topics: Acetates; Analgesics; Animals; Anti-Inflammatory Agents; Drug Design; Gastric Mucosa; Ibuprofen; Inf

2011
Synthesis, hydrolysis studies and phamacodynamic profiles of amide prodrugs of dexibuprofen with amino acids.
    Journal of enzyme inhibition and medicinal chemistry, 2011, Volume: 26, Issue:5

    Topics: Amides; Amino Acids; Analgesics; Animals; Anti-Inflammatory Agents; Chemical Phenomena; Feces; Human

2011
Synthesis and evaluation of anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation properties of new 2-(4-isobutylphenyl)propanoic acid derivatives.
    Journal of enzyme inhibition and medicinal chemistry, 2012, Volume: 27, Issue:1

    Topics: Acute Disease; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Dise

2012
A fixed-dose combination ibuprofen and famotidine (Duexis).
    The Medical letter on drugs and therapeutics, 2011, Oct-31, Volume: 53, Issue:1376

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Combinations; Duodenal Ulcer; F

2011
Ibuprofen-phospholipid solid dispersions: improved dissolution and gastric tolerance.
    International journal of pharmaceutics, 2012, Jan-17, Volume: 422, Issue:1-2

    Topics: Administration, Oral; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemis

2012
Editorial: single-tablet ibuprofen/double-dose famotidine for reduction of gastric and duodenal ulcers (REDUCE Trials): what can be reduced?
    The American journal of gastroenterology, 2012, Volume: 107, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Female; Huma

2012
Thiazolo[3,2-b]-1,2,4-triazole-5(6H)-one substituted with ibuprofen: novel non-steroidal anti-inflammatory agents with favorable gastrointestinal tolerance.
    European journal of medicinal chemistry, 2012, Volume: 57

    Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Dose-Response Relationshi

2012
Synthesis and evaluation of antioxidant-s-(+)-Ibuprofen hybrids as gastro sparing NSAIDs.
    Medicinal chemistry (Shariqah (United Arab Emirates)), 2013, Volume: 9, Issue:7

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Chromatography, High Pressure Liquid

2013
Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties.
    European journal of medicinal chemistry, 2003, Volume: 38, Issue:5

    Topics: Acetic Acid; Administration, Oral; Amides; Analgesics, Non-Narcotic; Animals; Ibuprofen; Injections,

2003
[Gastrointestinal hemorrhages as complications of gastropathies associated with intake of nonsteroidal anti-inflammatory drugs].
    Terapevticheskii arkhiv, 2003, Volume: 75, Issue:5

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diclofenac; Duodenal Ulcer; Duodeno

2003
Synthesis and analgesic-anti-inflammatory activities of some 1,2,4-triazine derivatives.
    Arzneimittel-Forschung, 2004, Volume: 54, Issue:1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Edema; Ibuprofen; Indicators and Reag

2004
Antiinflammatory and antiulcer activities of phytic acid in rats.
    Indian journal of experimental biology, 2004, Volume: 42, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Cold Temperature; Ethanol; Famotidine; Gastric

2004
Evidence in practice--number 3: Cox 2 inhibitors.
    The British journal of general practice : the journal of the Royal College of General Practitioners, 2004, Volume: 54, Issue:508

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Evidence-Based Medic

2004
Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor.
    European journal of pharmacology, 2004, Nov-28, Volume: 505, Issue:1-3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Proliferation; Cyclooxygenase 2; C

2004
Taurine prevents Ibuprofen-induced gastric mucosal lesions and influences endogenous antioxidant status of stomach in rats.
    TheScientificWorldJournal, 2004, Dec-06, Volume: 4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Catalase; Female; Gastric Mucosa; Gl

2004
COX expression and PGE(2) and PGD(2) production in experimental acute and chronic gastric lesions.
    International immunopharmacology, 2005, Volume: 5, Issue:2

    Topics: Acetic Acid; Acute Disease; Animals; Chronic Disease; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge

2005
Administration of L-arginine reduces the delay of the healing process caused by ibuprofen. Implication of COX and growth factors expression.
    Histology and histopathology, 2005, Volume: 20, Issue:2

    Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Chronic Disease; Cyclooxyge

2005
Pterocarpus santalinus: a traditional herbal drug as a protectant against ibuprofen induced gastric ulcers.
    Phytotherapy research : PTR, 2005, Volume: 19, Issue:11

    Topics: Animals; Anti-Ulcer Agents; Cation Transport Proteins; Gastric Mucosa; Ibuprofen; Male; Phytotherapy

2005
Pharmacological activity and hydrolysis behavior of novel ibuprofen glucopyranoside conjugates.
    European journal of medicinal chemistry, 2006, Volume: 41, Issue:11

    Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Edema; Female

2006
Effect of different cyclooxygenase inhibitors on gastric adaptive cytoprotection induced by 20% ethanol.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:2

    Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytoprotection; D

2007
Gastrointestinal bleeding in children following ingestion of low-dose ibuprofen.
    Journal of pediatric gastroenterology and nutrition, 2007, Volume: 44, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Female; Gastritis; Gastrointestinal Hemor

2007
Nurofen Plus misuse: an emerging cause of perforated gastric ulcer.
    The Medical journal of Australia, 2008, Jan-07, Volume: 188, Issue:1

    Topics: Abdominal Pain; Adult; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Codeine; Drug Co

2008
Comparative gastric ulcerogenic effects of meseclazone, 5-chlorosalicylic acid and other nonsteroidal anti-inflammatory drugs following acute and repeated oral administration to rats.
    Toxicology and applied pharmacology, 1980, Mar-15, Volume: 52, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Benzoxazines; Biotransformation; Fenoprofen; Ibuprofen; Indometha

1980
Gastric anti-ulcer activity of (+)-cyanidanol-3, a histidine decarboxylase inhibitor.
    European journal of pharmacology, 1981, Jan-05, Volume: 69, Issue:1

    Topics: Animals; Anti-Ulcer Agents; Aspirin; Benzopyrans; Carboxy-Lyases; Catechin; Female; Gastric Acidity

1981
Effects of nonsteroidal antiinflammatory drugs on ulcerogenesis and gastric secretion in pylorus-ligated rat.
    Digestive diseases and sciences, 1995, Volume: 40, Issue:1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dinoprostone; Gastric Acid; Gastric Mucos

1995
Another case of gastric perforation associated with administration of ibuprofen in a dog.
    Journal of the American Veterinary Medical Association, 1993, Mar-01, Volume: 202, Issue:5

    Topics: Animals; Dog Diseases; Dogs; Ibuprofen; Male; Peptic Ulcer Perforation; Stomach Ulcer

1993
NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions.
    General pharmacology, 1993, Volume: 24, Issue:1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Carrageenan; Cyclooxygena

1993
A case-control study of acute ibuprofen toxicity in dogs.
    Preventive veterinary medicine, 1998, May-01, Volume: 35, Issue:2

    Topics: Acute Kidney Injury; Animals; Case-Control Studies; Dog Diseases; Dogs; Duodenal Ulcer; Female; Gast

1998
Pyloric channel stricture secondary to high-dose ibuprofen therapy in a patient with cystic fibrosis.
    The Annals of pharmacotherapy, 1999, Volume: 33, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Catheterization; Child; Cystic Fibrosis; Female; Humans; Ib

1999
NSAIDs and alcohol: never the twain shall mix?
    The American journal of gastroenterology, 1999, Volume: 94, Issue:11

    Topics: Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 1; Cyclooxygenase

1999
The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption.
    The American journal of gastroenterology, 1999, Volume: 94, Issue:11

    Topics: Acute Disease; Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Contro

1999
Synthesis and characterization of a diruthenium-ibuprofenato complex comparing its anti-inflammatory activity with that of a copper(II)-ibuprofenato complex.
    Journal of inorganic biochemistry, 2000, Jul-15, Volume: 81, Issue:1-2

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Edema; Gastrointestinal Hemorrhage; I

2000
Effect of dimethylglycine on gastric ulcers in rats.
    The Journal of pharmacy and pharmacology, 2000, Volume: 52, Issue:12

    Topics: Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Famotidine; Gastric Juice; Glutathione

2000
Activity profile of glycolamide ester prodrugs of ibuprofen.
    Drug development and industrial pharmacy, 2001, Volume: 27, Issue:1

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Edema; Esters;

2001
Alkyl ester prodrugs for improved topical delivery of ibuprofen.
    Indian journal of experimental biology, 2001, Volume: 39, Issue:3

    Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Edema; Ibuprofen; Prodrug

2001
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
    BMJ (Clinical research ed.), 2002, Jun-01, Volume: 324, Issue:7349

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase

2002
[Irritative activity of a new anti-inflammatory agent 4-(p-chorophenyl)-2-phenyl-5-thiazoleacetic acid (CH-800) on the gastrointestinal tract in rats (author's transl)].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1979, Volume: 75, Issue:8

    Topics: Acetates; Administration, Oral; Animals; Anti-Inflammatory Agents; Aspirin; Diclofenac; Digestive Sy

1979
Some aspects of the pharmacology of butibufen, a non-steroidal anti-inflammatory agent.
    Archives internationales de pharmacodynamie et de therapie, 1977, Volume: 227, Issue:1

    Topics: Acetates; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Aspirin; Edema; Gr

1977
Gastric perforation associated with administration of ibuprofen in a dog.
    Journal of the American Veterinary Medical Association, 1992, Dec-01, Volume: 201, Issue:11

    Topics: Animals; Anorexia; Dog Diseases; Dogs; Duodenostomy; Female; Gastrostomy; Ibuprofen; Peptic Ulcer Pe

1992
[The results of the endoscopic diathermy coagulation of hemorrhaging gastroduodenal ulcers].
    Khirurgiia, 1992, Issue:2

    Topics: Acute Disease; Duodenal Ulcer; Electrocoagulation; Female; Hemostasis, Endoscopic; Humans; Ibuprofen

1992
Potentiation of gastric toxicity of ibuprofen by paracetamol in the rat.
    The Journal of pharmacy and pharmacology, 1991, Volume: 43, Issue:7

    Topics: Acetaminophen; Administration, Oral; Animals; Drug Synergism; Gastric Mucosa; Ibuprofen; Male; Rats;

1991
Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer.
    Lancet (London, England), 1986, Mar-01, Volume: 1, Issue:8479

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Duodenal Ulcer; Female; Humans; Ibuprofen; Indome

1986
Selected pharmacological and immunopharmacological indices of ibuprofen.
    Archivum immunologiae et therapiae experimentalis, 1987, Volume: 35, Issue:2

    Topics: Animals; Antibody-Producing Cells; Guinea Pigs; Humans; Ibuprofen; Immune System; In Vitro Technique

1987
Therapeutic efficacy and gastric tolerance of ibuprofen (Brufen) at 1600-2400 mg dosage in rheumatoid arthritis.
    The British journal of clinical practice, 1987, Volume: 41, Issue:12

    Topics: Adult; Arthritis, Rheumatoid; Female; Gastric Mucosa; Humans; Ibuprofen; Male; Stomach Ulcer

1987
Effect of acetaminophen on human gastric mucosal injury caused by ibuprofen.
    Gut, 1986, Volume: 27, Issue:4

    Topics: Acetaminophen; Adult; Female; Gastric Mucosa; Humans; Ibuprofen; Male; Middle Aged; Stomach Ulcer; T

1986